Minimal Residual Disease Testing Market Size & Opportunities Analysis - Growth Strategies, Competitiveness, and Forecasts (2025 - 2032)

Minimal Residual Disease Testing Market Emerging Trends

Growing Adoption of Liquid Biopsy for MRD Detection Is a Trend

• The increasing use of liquid biopsy for MRD detection establishes itself as an important trend because it brings fundamental changes to minimal residual disease surveillance processes.
• The advancement of liquid biopsy as an MRD detection tool results from the wider oncological emphasis on diagnostic methods that use noninvasive approaches along with real-time disease surveillance and precise treatment solutions.
• The MRD testing process has evolved through liquid biopsy technology which provides patients with easier and friendlier testing options instead of bone marrow biopsies while following the healthcare industry's objectives for non-invasive diagnostic methods.
• The expansion of minimal residual disease testing to solid tumors creates a natural place for liquid biopsy because it can detect circulating tumor DNA in bodily fluids.
• The adoption of liquid biopsy represents a permanent shift in healthcare which advances through technological breakthroughs and improves clinical evidence and regulatory and provider approval.

Advancements in Next-Generation Sequencing and Polymerase Chain Reaction Technologies

• The minimal residual disease (MRD) testing market receives growth impetus from next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies because these systems enhance MRD detection precision accessibility and medical acceptance.
• These technologies produce ultrahigh detection sensitivity for cancer cells that used to be impossible to detect thus enabling physicians to make better treatment plans.
• Their better precision enhances adoption rates among clinical practitioners researchers and pharmaceutical organizations thereby facilitating their entry into standard cancer care and clinical trial programs.
• The implementation of innovative technologies lowered expenditures while streamlining operations which makes MRD testing accessible to a wider scope of healthcare facilities.
• Market growth gets direct support from NGS and PCR enhancements that simplify accessibility enhance diagnostic precision and turn MRD testing into the essential foundation of personalized cancer treatment.

Minimal Residual Disease Testing Market Segmentation Analysis

Test Type Analysis

The DNA-based category held the largest market share, of 65%, in 2024, because they provide superior sensitivity combined with high accuracy while earning broad clinical acceptance. Next-generation sequencing (NGS) and polymerase chain reaction (PCR) technology-based tests use their sensitive detection systems to identify tiny amounts of tumor DNA found in blood or bone marrow samples. Guardant Health together with Adaptive Biotechnologies and Roche use substantial investments to lead the market while developing DNA-based MRD assays. The number of routine clinical applications increased through regulatory approvals and insurance reimbursements leading to additional market penetration.

The RNA-based category will grow at a highest CAGR, during the forecast period. Real-time monitoring of aggressive evolving cancers benefits greatly from these tests because they enable essential treatment modifications. The rapid expansion of this market category results from recent developments in single-cell RNA sequencing and liquid biopsy approaches while pharmaceutical companies and research institutions study RNA biomarkers to predict immunotherapy responses. The worldwide surge of RNA-based tests in precision oncology occurs because pharmaceutical firms and research laboratories are investing in personalized medicine applications.

The test types analyzed here are:

• DNA-Based (Largest Category)
• RNA-Based (Fastest-Growing Category)
• Immunological

Application Analysis

The hematological malignancies category held the larger market share, of 60%, in 2024. Different treatment methods rely on MRD testing because clinicians use this approach for decision-making relapse detection and therapy adjustments in blood cancer patients. The FDA and EMA together with other regulatory bodies have accepted MRD status as an acceptable surrogate endpoint when conducting clinical trials for hematologic cancers so adoption rates increase. Flow cytometry alongside PCR and NGS-based assays have proven their wide validation for leukemia and lymphoma MRD assessment thus becoming the primary diagnostic targets for laboratory advancement and commercial product development. The solid tumors category will grow at a higher CAGR, during the forecast period. This is due to recently developed liquid biopsy techniques even though historical use has concentrated on hematologic cancers. The rapid rise of circulating tumor DNA based tests used for cancer monitoring in lung, colorectal, and breast cancer fuels sector expansion. The expansion of MRD testing relies on Guardant Health and Natera through their development of sensitive ctDNA assays which enable noninvasive monitoring of MRD along with recurrence detection. The rapid growth of this segment will follow clinical validation and oncologist integration of MRD testing into solid tumor care management.

The applications analyzed here are:

• Hematological Malignancies (Larger Category)
  • Leukemia
  • Lymphoma
• Solid Tumors (Faster-Growing Category)

Technology Analysis

The polymerase chain reaction category held the largest market share, of 70%, in 2024. This is because it provides excellent sensitivity together with cost-effective performance and widespread clinical acceptance. The technique shows exceptional ability to identify even tiny amounts of residual cancer cells through its genetic sequence amplification process. The accuracy and reliability of MRD detection improved with digital PCR (dPCR) and quantitative PCR (qPCR). The MRD assay segment of Bio-Rad Laboratories, Roche, and Adaptive Biotechnologies leads through their high-precision PCR testing which currently appears in hematologic malignancies. PCR remains the most popular method for MRD detection because it has received strong regulatory approval and treatment guideline endorsement.

The next-generation sequencing category will grow at a highest CAGR, during the forecast period, because it provides unmatched genetic analysis depth combined with ultra-sensitive MRD detection capabilities that receive increasing clinical use across solid tumors and hematologic malignancies. NGS surpasses PCR in terms of genetic assessment breadth since it provides broad tumor analysis capabilities that enhance personalized cancer care and disease relapse risk estimation. The market adoption of NGS has received a boost from two main developments, liquid biopsy-based minimal residual disease detection and advances in biomedical informatics and automated laboratory systems. The rapid expansion of the ctDNA-based MRD assay market is driven by Guardant Health, Natera, and Roche who are leading the innovation efforts.

The technologies analyzed here are:

• Next-Generation Sequencing (NGS) (Fastest-Growing Category)
• Polymerase Chain Reaction (PCR) (Largest Category)
• Flow Cytometry
• Fluorescence In-Situ Hybridization (FISH)

End User Analysis

The hospitals category held the largest market share, of 75%, in 2024, since they are major centers for cancer diagnosis, treatment, and monitoring after treatment. They possess advanced diagnostic facilities, which allow them to utilize PCR, NGS, and flow cytometry-based MRD assays. Hospitals also collaborate with oncologists and hematologists to incorporate MRD testing into treatment protocols, especially for leukemia, lymphoma, and solid tumors. The large patient base, access to funding, and partnerships with diagnostic firms further enhance their market leadership.

The diagnostic laboratories category will grow at a highest CAGR, during the forecast period, as the demand for specialized and outsourced MRD testing services increases. As liquid biopsy-based MRD tests and NGS-based assays grow, Labcorp, Quest Diagnostics, and NeoGenomics, among other labs, are now increasingly providing high-throughput, cost-efficient MRD testing solutions. Furthermore, collaborations between labs and biotech firms have widened the reach of advanced MRD assays beyond hospitals, driving high growth in the market.

The end users analyzed here are:

• Hospitals (Largest Category)
• Specialty Clinics
• Diagnostic Laboratories (Fastest-Growing Category)
• Research and Academic Institutes

Minimal Residual Disease Testing Market Regional Growth Dynamics

The North America held the largest market share, of 40%, in 2024. This is fueled by robust healthcare infrastructure, high uptake of sophisticated diagnostics, and huge investments in precision medicine. The availability of prominent industry players like Guardant Health, Natera, Adaptive Biotechnologies, and Bio-Rad Laboratories also enhances the region's leadership. Moreover, the FDA's backing of MRD testing as a clinical endpoint and insurance reimbursement for MRD assays have helped fuel growth in the market. The high incidence of hematologic malignancies and solid tumors, along with the ith growing adoption of liquid biopsy-based MRD tests, further established the dominance of North America.

The market in the APAC region will grow at a higher CAGR, during the forecast period, due to increasing cancer incidence, growing healthcare expenditure, and escalating adoption of innovative diagnostic technologies. China, Japan, and India are all expanding their oncology testing capacity rapidly, aided by government efforts and global partnerships. The expanding access to NGS and PCR-based MRD tests, coupled with a greater number of cancer diagnostic clinical trials, are stimulating market growth.

Moreover,thearea is also experiencing an increase in collaboration between regional healthcare organizations and international diagnostic firms, which is also increasing the availability and affordability of MRD testing.

The regions analyzed in this report are:

• North America (Largest Region)
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
• Asia-Pacific (Fastest-Growing Region)
  • Japan
  • China
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • U.A.E.

Minimal Residual Disease Testing Market Competitive Landscape

The market shows fragmentation because it includes various companies that offer Next-Generation Sequencing (NGS), Polymerase Chain Reaction, (PCR) and Flow Cytometry technologies. The market segmentations stem from three major groups namely established firms and emerging startups alongside diagnostic companies from different regions which focus their testing approaches on distinct applications. As a leading pharmaceutical company F. Hoffmann-La Roche Ltd. maintains its industry dominance through its expansive diagnostic offerings and international scale and strategic investments in precision cancer solutions strong competition exists between companies that pursue acquisitions and collaborative agreements to increase their market presence. This industry encompasses the assessment of hematologic malignancies together with solid tumors alongside the identification of MRD through liquid biopsy methods for both diagnostic medical practices and pharmaceutical scientific research purposes

Minimal Residual Disease Testing Market News

• In March 2025, Exact Sciences earned the 2025 Gallup Exceptional Workplace Award two consecutive times because of its powerful workplace culture. High employee engagement combined with improved performance is the key criterion for organizational recognition through the award. Exact Sciences attributes its success to a collaborative and mission-driven work environment.
• In February 2025, Bio-Rad Laboratories offered acquisition to Stilla Technologies which specializes in digital PCR solution development. The agreement seeks to increase Bio-Rad's market presence in molecular diagnostics as well as MRD testing. This agreement supports Bio-Rad's corporate plan to grow its precision medicine offerings.